JP2006519811A - 5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸を含む医薬組成物 - Google Patents
5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸を含む医薬組成物 Download PDFInfo
- Publication number
- JP2006519811A JP2006519811A JP2006504648A JP2006504648A JP2006519811A JP 2006519811 A JP2006519811 A JP 2006519811A JP 2006504648 A JP2006504648 A JP 2006504648A JP 2006504648 A JP2006504648 A JP 2006504648A JP 2006519811 A JP2006519811 A JP 2006519811A
- Authority
- JP
- Japan
- Prior art keywords
- liquid oral
- formulation
- methyl
- oral dosage
- suspension
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (22)
- 水、5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸、および懸濁剤を含む製剤であって、約4.3から約5.5の間のpHである液体経口投与製剤。
- 該懸濁剤が、微結晶セルロース、カルボキシメチルセルロースナトリウム、グアールガム、キサンタンガム、ゲランガム、カラギーナン、グリコールスターチナトリウム、およびその混合物からなる群から選択されるものである、請求項1記載の液体経口投与製剤。
- 湿潤剤をさらに含む、請求項2記載の液体経口投与製剤。
- 該湿潤剤が、ポリソルベート80、ポロキサマー、ポリエトキシル化ヒマシ油、ポリエトキシル化水素化ヒマシ油、ステアリン酸ポリオキシル40、およびそれらの混合物からなる群から選択されるものである、請求項3記載の液体経口投与製剤。
- 該製剤のpHが、約4.5から5.5の間である、請求項2記載の液体経口投与製剤。
- 該製剤のpHが、約4.75から約5.25の間である、請求項6記載の液体経口投与製剤。
- 該製剤のpHが約5.0であって、該ポロキサマーがポロキサマー188である、請求項7記載の液体経口投与製剤。
- 該懸濁剤が、微結晶セルロースとカルボキシメチルセルロースナトリウムの混合物である、請求項1記載の液体経口投与製剤。
- 緩衝系を包含する、請求項8記載の液体経口投与製剤。
- 該緩衝系が、クエン酸とアルカリ金属クエン酸塩、酢酸とアルカリ金属酢酸塩、コハク酸とアルカリ金属コハク酸塩、およびそれらの混合物からなる群から選択されるものである、請求項9記載の液体経口投与製剤。
- 消泡剤をさらに含む、請求項9記載の液体経口投与製剤。
- 保存料をさらに含む、請求項9記載の液体経口投与製剤。
- 該保存料が、安息香酸、ソルビン酸、ブチルパラベン、エチルパラベン、メチルパラベン、プロピルパラベン、安息香酸ナトリウム、プロピオン酸ナトリウム、およびそれらの混合物からなる群から選択されるものである、請求項12記載の液体経口投与製剤。
- 5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸を含む経口懸濁液を製造する方法であって、以下:
水、薬剤物質、および懸濁剤を混合し、最初の混合物を得、その後、緩衝系成分を混合する工程;または、
水、懸濁剤および緩衝系成分を混合し、最初の混合物を得、その後、薬剤物質を混合する工程、
を含む方法。 - 該懸濁剤が、微結晶セルロースとカルボキシメチルセルロースナトリウムの混合物である、請求項14記載の方法。
- 該経口懸濁液が、約4.3から5.5の間のpHである、請求項15記載の方法。
- 該緩衝系成分が、クエン酸およびクエン酸ナトリウムである、請求項16記載の方法。
- 該経口懸濁液が、約5.0のpHである、請求項17記載の方法。
- 5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸の懸濁液の溶解性および分解性を最小にする方法であって、5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸の懸濁液を提供すること、および該懸濁液のpHを約4.3から約5.5の間に調整することを含む方法。
- 該pHを約5.0に調整する、請求項19記載の方法。
- 5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸を含む液体経口投与製剤の有効量を投与することを含む、シクロオキシゲナーゼ−2依存性の疾患または状態を処置する方法であって、該製剤のpHが、約4.3から5.5の間である方法。
- 該製剤のpHが、約5.0である、請求項22記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45414503P | 2003-03-12 | 2003-03-12 | |
PCT/EP2004/002528 WO2004080451A1 (en) | 2003-03-12 | 2004-03-11 | Pharmaceutical composition comprising 5-methyl-2-2’-(chloro-6’-fluoroanilino) phe nylacetic acid |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006519811A true JP2006519811A (ja) | 2006-08-31 |
JP4580921B2 JP4580921B2 (ja) | 2010-11-17 |
Family
ID=32990870
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006504648A Expired - Fee Related JP4580921B2 (ja) | 2003-03-12 | 2004-03-11 | 5−メチル−2−(2’−クロロ−6’−フルオロアニリノ)フェニル酢酸を含む医薬組成物 |
Country Status (30)
Country | Link |
---|---|
US (2) | US20060094787A1 (ja) |
EP (1) | EP1603550B1 (ja) |
JP (1) | JP4580921B2 (ja) |
KR (1) | KR20050109077A (ja) |
CN (1) | CN100345536C (ja) |
AR (1) | AR043536A1 (ja) |
AT (1) | ATE418332T1 (ja) |
AU (1) | AU2004218921B2 (ja) |
BR (1) | BRPI0408270A (ja) |
CA (1) | CA2518393A1 (ja) |
CL (1) | CL2004000496A1 (ja) |
DE (1) | DE602004018622D1 (ja) |
EC (1) | ECSP055998A (ja) |
ES (1) | ES2318277T3 (ja) |
HK (1) | HK1086492A1 (ja) |
HR (1) | HRP20050787A2 (ja) |
IL (1) | IL170518A (ja) |
IS (1) | IS2658B (ja) |
MA (1) | MA27670A1 (ja) |
MX (1) | MXPA05009686A (ja) |
MY (1) | MY139455A (ja) |
NO (1) | NO20054662L (ja) |
NZ (1) | NZ542218A (ja) |
PE (1) | PE20041063A1 (ja) |
PT (1) | PT1603550E (ja) |
RU (1) | RU2363462C2 (ja) |
TN (1) | TNSN05222A1 (ja) |
TW (1) | TWI327913B (ja) |
WO (1) | WO2004080451A1 (ja) |
ZA (1) | ZA200506750B (ja) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2541265A1 (en) * | 2003-10-08 | 2005-04-28 | Novartis Ag | Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
KR100900915B1 (ko) * | 2007-05-07 | 2009-06-05 | 이연제약주식회사 | 메게스트롤 아세테이트를 함유하는 현탁액 제제 및 이의제조방법 |
EP2222273A2 (en) * | 2007-11-12 | 2010-09-01 | Novartis AG | Liquid compositions comprising valsartan |
EP2926810A1 (en) * | 2014-03-31 | 2015-10-07 | Sanovel Ilac Sanayi ve Ticaret A.S. | Oral liquid pharmaceutical formulations of loxoprofen |
EP3471725A4 (en) | 2016-06-16 | 2020-01-22 | Cutispharma, Inc. | COMPOSITION AND METHOD FOR SUSPENDING A PROTON PUMP INHIBITOR |
CA3036356A1 (en) | 2016-09-09 | 2018-03-15 | Cutispharma, Inc. | Suspensions and diluents for metronidazole and baclofen |
WO2018237327A1 (en) | 2017-06-22 | 2018-12-27 | Triact Therapeutics, Inc. | METHODS OF TREATING GLIOBLASTOMA |
WO2019067991A1 (en) * | 2017-09-29 | 2019-04-04 | Triact Therapeutics, Inc. | INIPARIB FORMULATIONS AND USES THEREOF |
US11633478B2 (en) | 2019-07-16 | 2023-04-25 | Azurity Pharmaceuticals, Inc. | Compositions and kits for Omeprazole suspension |
US10751333B1 (en) | 2019-07-16 | 2020-08-25 | Cutispharma, Inc. | Compositions and kits for omeprazole suspension |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004527458A (ja) * | 2000-09-11 | 2004-09-09 | ノバルティス アクチエンゲゼルシャフト | 医薬組成物 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5112604A (en) * | 1989-09-01 | 1992-05-12 | Riker Laboratories, Inc. | Oral suspension formulation |
US5840768A (en) * | 1997-06-04 | 1998-11-24 | Fmc Corporation | MCC: alginate pharmaceutical suspensions |
US6103260A (en) * | 1997-07-17 | 2000-08-15 | Mcneil-Ppc, Inc. | Simethicone/anhydrous calcium phosphate compositions |
CO4960662A1 (es) * | 1997-08-28 | 2000-09-25 | Novartis Ag | Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados |
US20020028794A1 (en) * | 2000-07-21 | 2002-03-07 | Brubaker Greg Allen | Megestrol acetate suspension |
BR0306726A (pt) * | 2002-01-07 | 2004-12-21 | Pharmacia Corp | Mistura de fármacos com melhor taxa de dissolução |
US20030203915A1 (en) * | 2002-04-05 | 2003-10-30 | Xinqin Fang | Nitric oxide donors, compositions and methods of use related applications |
-
2004
- 2004-03-09 TW TW093106228A patent/TWI327913B/zh not_active IP Right Cessation
- 2004-03-10 AR ARP040100769A patent/AR043536A1/es not_active Application Discontinuation
- 2004-03-10 PE PE2004000262A patent/PE20041063A1/es not_active Application Discontinuation
- 2004-03-11 WO PCT/EP2004/002528 patent/WO2004080451A1/en active IP Right Grant
- 2004-03-11 CL CL200400496A patent/CL2004000496A1/es unknown
- 2004-03-11 KR KR1020057016860A patent/KR20050109077A/ko not_active Application Discontinuation
- 2004-03-11 MX MXPA05009686A patent/MXPA05009686A/es active IP Right Grant
- 2004-03-11 US US10/549,249 patent/US20060094787A1/en not_active Abandoned
- 2004-03-11 CN CNB2004800056641A patent/CN100345536C/zh not_active Expired - Fee Related
- 2004-03-11 ES ES04719398T patent/ES2318277T3/es not_active Expired - Lifetime
- 2004-03-11 DE DE602004018622T patent/DE602004018622D1/de not_active Expired - Lifetime
- 2004-03-11 NZ NZ542218A patent/NZ542218A/en not_active IP Right Cessation
- 2004-03-11 MY MYPI20040851A patent/MY139455A/en unknown
- 2004-03-11 AT AT04719398T patent/ATE418332T1/de active
- 2004-03-11 RU RU2005131310/15A patent/RU2363462C2/ru not_active IP Right Cessation
- 2004-03-11 AU AU2004218921A patent/AU2004218921B2/en not_active Ceased
- 2004-03-11 JP JP2006504648A patent/JP4580921B2/ja not_active Expired - Fee Related
- 2004-03-11 CA CA002518393A patent/CA2518393A1/en not_active Abandoned
- 2004-03-11 PT PT04719398T patent/PT1603550E/pt unknown
- 2004-03-11 BR BRPI0408270-2A patent/BRPI0408270A/pt not_active IP Right Cessation
- 2004-03-11 EP EP04719398A patent/EP1603550B1/en not_active Expired - Lifetime
-
2005
- 2005-08-23 ZA ZA200506750A patent/ZA200506750B/xx unknown
- 2005-08-25 IL IL170518A patent/IL170518A/en not_active IP Right Cessation
- 2005-09-02 EC EC2005005998A patent/ECSP055998A/es unknown
- 2005-09-08 HR HR20050787A patent/HRP20050787A2/xx not_active Application Discontinuation
- 2005-09-09 TN TNP2005000222A patent/TNSN05222A1/en unknown
- 2005-09-28 IS IS8049A patent/IS2658B/is unknown
- 2005-09-30 MA MA28525A patent/MA27670A1/fr unknown
- 2005-10-11 NO NO20054662A patent/NO20054662L/no not_active Application Discontinuation
-
2006
- 2006-06-08 HK HK06106599.6A patent/HK1086492A1/xx not_active IP Right Cessation
-
2008
- 2008-10-07 US US12/287,231 patent/US20090048344A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004527458A (ja) * | 2000-09-11 | 2004-09-09 | ノバルティス アクチエンゲゼルシャフト | 医薬組成物 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10238640B2 (en) | Pharmaceutical suspension composition | |
US6806256B2 (en) | Taste masked liquid pharmaceutical compositions | |
JP6273589B2 (ja) | 安定化されたカリスバメートの小児用懸濁液 | |
JP4445590B2 (ja) | パロキセチン−レジン含有の経口液体組成物 | |
US20090048344A1 (en) | Pharmaceutical composition comprising 5-methyl-2-2' (chloro-6'-fluoroanilino phe nylacetic acid | |
EP1450749A1 (en) | Taste masked aqueous liquid pharmaceutical composition | |
JP2011503105A (ja) | バルサルタン含有液体組成物 | |
EP2838510A1 (en) | Atomoxetine solution | |
US20060198856A1 (en) | Ibuprofen suspension stabilized with docusate sodium | |
AU2008321159B2 (en) | Liquid compositions comprising valsartan | |
WO2021105524A1 (es) | Composición farmacéutica de la sal de ibuprofeno con lisina en forma de solución oral |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100615 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100804 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20100824 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20100830 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130903 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |